Use of Thiazolidinediones and the Risk of Colorectal Cancer in Patients With Diabetes
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Preclinical data suggest that peroxisome proliferator–activated receptor γ (PPARγ) agonists have antineoplastic effects in colorectal cancer. We aimed to assess the association between the use of synthetic PPARγ agonists, represented by thiazolidinediones (TZDs), and the risk of developing colorectal cancer. RESEARCH DESIGN AND METHODS: We conducted a nationwide, population-based, case-control study using the Taiwan National Health Insurance Research Database. Case subjects were defined as patients who were diagnosed with diabetes at least 365 days prior to a new diagnosis of colorectal cancer between 2000 and 2008. We randomly selected diabetic control subjects for each case subject, which were matched by sex, age, and the duration of diabetes. Among the 24,496 eligible case subjects and control subjects, we used conditional logistic regression to assess the risk of colorectal cancer in association with the use of TZDs. An additional analysis was conducted to assess the effects of concomitant use of TZDs and low-dose aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) on the risk of colorectal cancer. RESULTS: A decreased risk of colorectal cancer was observed in patients who had used TZDs compared with those who had never used TZDs (adjusted odds ratio 0.86 [95% CI 0.79–0.94]). Furthermore, the benefit of a decreased colorectal cancer risk was also found with concomitant use of TZDs and low-dose aspirin or NSAIDs. CONCLUSIONS: The use of TZDs may be associated with a decreased risk of colorectal cancer in patients with diabetes. Further studies are warranted to confirm our findings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Other research suggests that PPAR-γ agonists might prevent certain cancers.50,51”
From Pioglitazone after Ischemic Stroke or Transient Ischemic Attack (2016) · cites this paper as [51]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The nuclear receptor superfamily: the second decade
Mangelsdorf, D. J., Thummel, C., Beato, M., Herrlich, P., Schütz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., Chambon, P., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90199-x · Cited by 6,964 · cited 1×
“The PPARs are ligand-activated transcription factors that modulate gene expression (1,2).”
Background15-Deoxy-Δ12,14-Prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ
Forman, B. M., Tontonoz, P., Chen, J., Brun, R. P., Spiegelman, B. M., & Evans, R. M. (1995) · Cell · doi:10.1016/0092-8674(95)90193-0 · Cited by 2,858
Self-citationDiabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
The Emerging Risk Factors Collaboration (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1008862 · Cited by 2,726
Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · Diabetes Care · doi:10.2337/dc10-0666 · Cited by 2,366 · cited 1×
“Appropriately, glucose control plays a role in effective diabetes management, which may lessen morbidity and mortality by reducing the risk of diabetes-associated complications (30).”
BackgroundRoles of PPARs in health and disease
Kersten, S., Desvergne, B., & Wahli, W. (2000) · Nature · doi:10.1038/35013000 · Cited by 1,956 · cited 1×
“The PPARs are ligand-activated transcription factors that modulate gene expression (1,2).”
BackgroundRothwell, P. M., Wilson, M., Elwin, C.-E., Norrving, B., Algra, A., Warlow, C. P., & Meade, T. W. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61543-7 · Cited by 1,351 · cited 1×
“Low-dose aspirin was widely recommended for the primary prevention of cardiovascular events in patients with diabetes, and it has been suggested to reduce incidence and mortality due to colorectal cancer (24,25).”
BackgroundDifferentiation and reversal of malignant changes in colon cancer through PPARγ
Sarraf, P., Mueller, E., Jones, D., King, F. J., DeAngelo, D. J., Partridge, J. B., Holden, S. A., Chen, L. B., Singer, S., Fletcher, C., et al. (1998) · Nature Medicine · doi:10.1038/2030 · Cited by 988 · cited 2×
“PPARg is activated by several natural and synthetic ligands, and its activation elicits cell differentiation and induces cell cycle arrest and apoptosis (3,4).”
BackgroundFlossmann, E., & Rothwell, P. M. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60747-8 · Cited by 820
Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone
Lewis, J. D., Ferrara, A., Peng, T., Hedderson, M., Bilker, W. B., Quesenberry, C. P., Vaughn, D. J., Nessel, L., Selby, J., & Strom, B. L. (2011) · Diabetes Care · doi:10.2337/dc10-1068 · Cited by 625
Does Universal Health Insurance Make Health Care Unaffordable? Lessons From Taiwan
Lu, J.-F. R., & Hsiao, W. C. (2003) · Health Affairs · doi:10.1377/hlthaff.22.3.77 · Cited by 529 · cited 1×
“According to the NHI Act, false reports of diagnosis or inappropriateness of medical services will yield a severe penalty (17,19).”
Background
Cited by
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack
Kernan, W. N., Viscoli, C. M., Furie, K. L., Young, L. H., Inzucchi, S. E., Gorman, M., Guarino, P. D., Lovejoy, A. M., Peduzzi, P. N., Conwit, R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1506930 · Cited by 1,124
Chang, S.-H., Wu, L.-S., Chiou, M.-J., Liu, J.-R., Yu, K.-H., Kuo, C.-F., Wen, M.-S., Chen, W.-J., Yeh, Y.-H., & See, L.-C. (2014) · Cardiovascular Diabetology · doi:10.1186/s12933-014-0123-x · Cited by 225
Diabetes and cancer: Pathophysiological fundamentals of a ‘dangerous affair’
Cignarelli, A., Genchi, V. A., Caruso, I., Natalicchio, A., Perrini, S., Laviola, L., & Giorgino, F. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.04.002 · Cited by 161
Diabetes and Colorectal Cancer Risk: Clinical and Therapeutic Implications
Yu, G., Li, S.-F., Wei, R., & Jiang, Z. (2022) · Journal of Diabetes Research · doi:10.1155/2022/1747326 · Cited by 123
Do We Still Need Pioglitazone for the Treatment of Type 2 Diabetes? A risk-benefit critique in 2013
Schernthaner, G., Currie, C. J., & Schernthaner, G.-H. (2013) · Diabetes Care · doi:10.2337/dcs13-2031 · Cited by 100
Diabetes and cancer, common threads and missing links
Hua, F., Yu, J., & Hu, Z. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.02.006 · Cited by 90
Tseng, Y.-H., Tsan, Y.-T., Chan, W.-C., Sheu, W. H.-H., & Chen, P.-C. (2015) · Diabetes Care · doi:10.2337/dc15-0563 · Cited by 67
Self-citationThe biological and pharmacological connections between diabetes and various types of cancer
Wang, X., & Ding, S. (2021) · Pathology - Research and Practice · doi:10.1016/j.prp.2021.153641 · Cited by 64
A new dawn for the use of thiazolidinediones in cancer therapy
Joshi, H., Pal, T., & Ramaa, C. S. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.884708 · Cited by 54
“Benefit of a decreased colorectal cancer risk was also found with concomitant use of TZDs and low-dose aspirin or NSAIDs [44]”
BackgroundPioglitazone after Ischemic Stroke or Transient Ischemic Attack
Viscoli, C. M., Kernan, W. N., & Young, L. H. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1605904 · Cited by 50
Metformin and HER2-positive breast cancer: Mechanisms and therapeutic implications
Bashraheel, S. S., Kheraldine, H., Khalaf, S., & Moustafa, A. A. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114676 · Cited by 38
Thiazolidinediones and risk of colorectal cancer in patients with diabetes mellitus: A meta-analysis
Hu, T., Liu, Y., Jin, P., & Sun, X. (2018) · Saudi Journal of Gastroenterology · doi:10.4103/sjg.sjg_295_17 · Cited by 35
Management of Diabetes in Candidates for Liver Transplantation and in Transplant Recipients
Brodosi, L., Petta, S., Petroni, M. L., Marchesini, G., & Morelli, M. C. (2021) · Transplantation · doi:10.1097/tp.0000000000003867 · Cited by 36
Does long-term use of antidiabetic drugs changes cancer risk?
Liu, Y.-C., Nguyen, P.-A., Humayun, A., Chien, S.-C., Yang, H., Asdary, R. N., Syed-Abdul, S., Hsu, M., Moldovan, M. V., Yen, Y., et al. (2019) · Medicine · doi:10.1097/md.0000000000017461 · Cited by 31
“Our findings supported by Ramos-Nino et al,[27] Chen et al,[28] and Piccinni et al[29] who all reported similar findings.”
ResultChang, S., Wu, L., Lee, C., Kuo, C.-T., Liu, J., Wen, M., Chen, W.-J., See, L., & Yeh, Y. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.04.121 · Cited by 23
Self-citationDiabetes and cancer relationships (糖尿病与肿瘤的关联性)
Wang, T., Ning, G., & Bloomgarden, Z. (2013) · Journal of Diabetes · doi:10.1111/1753-0407.12057 · Cited by 21
“A recent Taiwanese case-control study also confirmed that the use of TZDs may be associated with a decreased risk of colorectal cancer in patients with diabetes.(67) For bladder cancer risk, rosiglitazone use was not significantly associated with elevated bladder cancer risk,(68) whereas controversy remains as to whet…”
BackgroundRanjan, G., Ranjan, S., Sunita, P., & Pattanayak, S. P. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03661-z · Cited by 24
Wu, L., Chang, S., Chang, G., Liu, J., Chan, Y., Lee, H., Wen, M., Chen, W.-J., Yeh, Y., Kuo, C.-T., et al. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0365-x · Cited by 19
Chemopreventive drugs: Mechanismsviainhibition of cancer stem cells in colorectal cancer
Kim, T. I. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i14.3835 · Cited by 17
Antitumor effects of energy restriction-mimetic agents: thiazolidinediones
Omar, H. A., Salama, S. A., Arafa, E. A., & Weng, J. (2013) · Biological Chemistry · doi:10.1515/hsz-2013-0139 · Cited by 12
Bojková, B., Orendáš, P., Kubatka, P., Péč, M., Kassayová, M., Kisková, T., & Kajo, K. (2014) · Pathology - Research and Practice · doi:10.1016/j.prp.2014.06.003 · Cited by 11
Hsieh, M., Hung, P., Hsieh, V. C., Liao, S.-H., & How, C. (2020) · International Journal of Clinical Practice · doi:10.1111/ijcp.13804 · Cited by 10
Role and application of hysterosalpingography and Fallopian tube recanalization.
Mallarini, G., & Saba, L. (2010) · PubMed · Cited by 10
Cancer biology in diabetes update: Focusing on antidiabetic drugs
Kawakita, E., & Kanasaki, K. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14152 · Cited by 8
Lai, S., Lin, C., & Liao, K. (2020) · Medicine · doi:10.1097/md.0000000000019833 · Cited by 8
Albini, A., Cantelmo, A. R., Mortara, L., Noonan, D. M., & Corso, G. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.07.008 · Cited by 8
Lee, K., Yeh, Y., Chang, S., See, L., Lee, C., Wu, L., Liu, J., Kuo, C.-T., & Wen, M. (2017) · Medicine · doi:10.1097/md.0000000000007507 · Cited by 7
Self-citationRole of high-fat diet on the effect of pioglitazone and melatonin in a rat model of breast cancer
Bojková, B., Orendáš, P., Kajo, K., Kubatka, P., Výbohová, D., Bálentová, S., Kružliak, P., Zulli, A., Demečková, V., Péč, M., et al. (2015) · European Journal of Cancer Prevention · doi:10.1097/cej.0000000000000195 · Cited by 6
Association between WHO First-Step Analgesic Use and Risk of Breast Cancer in Women of Working Age
Oh, H. S., & Seo, H. J. (2023) · Pharmaceuticals · doi:10.3390/ph16020323 · Cited by 6
Lee, J. H., & Kim, T. I. (2013) · Current Colorectal Cancer Reports · doi:10.1007/s11888-013-0198-x · Cited by 6
“Recently, several studies have reported that the use of thiazolidinediones may be associated with a decreased risk of CRC in patients with DM [33, 34], and PPARγ is currently considered a potential target for chemoprevention, on the basis of the findings of other preclinical studies [35, 36].”
BackgroundHsu, F., Lai, J., Huang, C., Lin, M., & Hsieh, Y. (2021) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1832 · Cited by 5
Chuang, S.-L., Chu, T. C., Juan, Y., Wang, T., Yang, Y., Wang, T.-A., Chao, Y., Lin, P.-J., Yang, Y., Wang, Y.-C., et al. (2025) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-24-1632 · Cited by 2
Insulin Resistance: A Link Between Obesity and Cancer
Sattar, S., Nisar, M. F., & Nwosu, O. K. (2021) · Springer eBooks · doi:10.1007/978-3-030-72999-8_5 · Cited by 1
Heresbach, D., & Pienkowski, P. (2014) · Acta Endoscopica · doi:10.1007/s10190-014-0411-z · Cited by 1
Heresbach, D., & Bulois, P. (2014) · Acta Endoscopica · doi:10.1007/s10190-014-0401-1
Progress in understanding of relationship between diabetes and colorectal cancer
Yu, G., & Jiang, Z. (2021) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v29.i23.1323
Yang, Y. Y., & Wang, K. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1849647
“This finding is reinforced by multiple case-control studies, consistently reporting adjusted odds ratios (aORs) for CRC between 0.86 and 0.94 among TZD users (Chen et al., 2013; Liao et al., 2019).”
Influential
Metadata
- Authors
- Chen, S.-W., Tsan, Y.-T., Chen, J.-D., Hsieh, H.-I., Lee, C.-H., Lin, H.-H., Wang, J.-D., Chen, P.-C., & Health Data Analysis in Taiwan Research Group
- Affiliations
- National Taiwan University (TW)
- Fu Jen Catholic University (TW)
- National Cheng Kung University (TW)
- Corresponding author
- Chen, Pau-Chung
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-01-17
- Volume
- 36
- Issue
- 2
- Pages
- 369-375
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3554275
- OpenAlex
- W2098056191
- Cited by
- 37
- References
- 28
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 2 · 2023: 2 · 2022: 1 · 2021: 5 · 2020: 2 · 2019: 2 · 2018: 2 · 2017: 1 · 2016: 3 · 2015: 3 · 2014: 6 · 2013: 4
- FWCI
- 1.56
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Screening and Detection
- Keywords
- thiazolidinediones, colorectal cancer, diabetes mellitus, PPARγ agonists, cancer risk, aspirin, nonsteroidal anti-inflammatory drugs, chemoprevention
- MeSH terms
- Adult, Aged, Diabetes Mellitus, Type 2, Female, Humans, Male, Middle Aged, Colorectal Neoplasms, Case-Control Studies, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.